Back
Canopy Growth 10K Form
Sell
40
WEED.TO
Canopy Growth
Last Price:
12.15
Seasonality Move:
80.62%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
2021-06-01 | 10K | WEED.TO/Canopy Growth Annual |
2021-02-09 | 10Q | WEED.TO/Canopy Growth Quarterly |
2020-11-09 | 10Q | WEED.TO/Canopy Growth Quarterly |
2020-08-10 | 10Q | WEED.TO/Canopy Growth Quarterly |
2020-07-29 | 10K | WEED.TO/Canopy Growth Annual |
2020-06-01 | 10K | WEED.TO/Canopy Growth Annual |
Receive WEED.TO News And Ratings
See the #1 stock for the next 7 days that we like better than WEED.TO
WEED.TO Financial Statistics
Sales & Book Value
Annual Sales: | $402.9M |
---|---|
Cash Flow: | $-33.05M |
Price / Cash Flow: | 0 |
Annual Sales: | $6.57 |
Price / Book: | 2.06 |
Profitability
EPS (TTM): | -20.42000 |
---|---|
Net Income (TTM): | $-1.21B |
Gross Margin: | $-104.14M |
Return on Equity: | -138.78% |
Return on Assets: | -56.43% |
Canopy Growth Earnings Forecast
Key Canopy Growth Financial Ratios
- The Gross Profit Margin over the past 14 years for WEED.TO is -25.85%.
- The Selling, General & Administrative Expenses for WEED.TO have been equal to 97.36% of Gross Profit Margin.
- The Research & Development expenses have been 5.39% of Revenue.
- The Interest Expense is -3.85% of Operating Income.
- The Net Earning history of WEED.TO is -813.63% of Total Revenues.
- Per Share Earnings over the last 14 years have been positive in 6 years.
Canopy Growth Stock Price Chart
Industry, Sector and Symbol
Stock Exchange: | TSX |
---|---|
Industry: | Pharmaceuticals |
Sector: | Health Care |
Current Symbol: | WEED.TO |
Website: | canopygrowth.com |
Debt
Debt-to-Equity Ratio: | 1.12 |
---|---|
Current Ratio: | 1.79 |
Quick Ratio: | 1.13 |
Price-to-Earnings
Trailing P/E Ratio: | 0 |
---|---|
Forward P/E Ratio: | 0 |
WEED.TO Technical Analysis vs Fundamental Analysis
Sell
40
Canopy Growth (WEED.TO)
is a Sell
Is Canopy Growth a Buy or a Sell?
-
Canopy Growth stock is rated a Sell
The current Canopy Growth [WEED.TO] share price is $12.15. The Score for WEED.TO is 40, which is 20% below its historic median score of 50, and infers higher risk than normal.